Mer­ck’s six-year deal strat­e­gy could de­liv­er a block­buster if hy­per­ten­sion drug is OK’d this month

With an FDA de­ci­sion ex­pect­ed next week for its blood pres­sure drug so­tater­cept, Mer­ck is hop­ing that its bun­dle of ac­qui­si­tions in re­cent years will lead to mul­ti­ple ap­provals and late-stage clin­i­cal wins.

The reg­u­la­tor is set to de­cide whether to ap­prove the pul­monary ar­te­r­i­al hy­per­ten­sion drug known as so­tater­cept by March 26. If ap­proved, the drug could gen­er­ate $1.9 bil­lion in sales in 2025, ac­cord­ing to Leerink Part­ners an­a­lyst Daina Gray­bosch.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER